Literature DB >> 32607944

Progress to Date in Advancing Stratified Medicine in Psoriasis.

Claire Reid1,2, Lis Cordingley3, Richard B Warren4,5, Christopher E M Griffiths4,5.   

Abstract

Stratified medicine is the tailoring of treatment to the individual characteristics of each patient. This is a challenging task in the context of psoriasis, a complex disease with a variety of phenotypic presentations and a comorbidity burden that extends beyond cutaneous manifestations. In recent years, considerable progress has been made in understanding the immunology of psoriasis, and this has informed the development of increasingly precise and efficacious therapies. However, not all patients respond to biologic therapy, and access is limited to patients with moderate to severe disease. However, subpopulations of patients are emerging with distinct patterns of response to therapy, largely determined by clinical and pharmacogenomic factors. Despite progress to date, the natural history of psoriasis remains poorly understood. It is likely that disease onset, progression, development of comorbidities and response to therapy are due to a combination of genetic, inflammatory and environmental factors. We envision that a greater understanding of the natural history of psoriasis will be a key factor in progressing a stratified medicine approach to patient care, as will earlier intervention in the course of the disease.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32607944     DOI: 10.1007/s40257-020-00533-z

Source DB:  PubMed          Journal:  Am J Clin Dermatol        ISSN: 1175-0561            Impact factor:   7.403


  44 in total

1.  Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: SUPREME study.

Authors:  A Costanzo; L Bianchi; M L Flori; G Malara; L Stingeni; M Bartezaghi; L Carraro; G Castellino
Journal:  Br J Dermatol       Date:  2018-08-14       Impact factor: 9.302

2.  HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis.

Authors:  Nick Dand; Michael Duckworth; David Baudry; Alice Russell; Charles J Curtis; Sang Hyuck Lee; Ian Evans; Kayleigh J Mason; Ali Alsharqi; Gabrielle Becher; A David Burden; Richard G Goodwin; Kevin McKenna; Ruth Murphy; Gayathri K Perera; Radu Rotarescu; Shyamal Wahie; Andrew Wright; Nick J Reynolds; Richard B Warren; Christopher E M Griffiths; Catherine H Smith; Michael A Simpson; Jonathan N Barker
Journal:  J Allergy Clin Immunol       Date:  2018-12-20       Impact factor: 10.793

3.  HLA-C*06:02 Allele and Response to IL-12/23 Inhibition: Results from the Ustekinumab Phase 3 Psoriasis Program.

Authors:  Katherine Li; C Chris Huang; Bruce Randazzo; Shu Li; Philippe Szapary; Mark Curran; Kim Campbell; Carrie Brodmerkel
Journal:  J Invest Dermatol       Date:  2016-07-29       Impact factor: 8.551

4.  Treatment of pustular psoriasis: from the Medical Board of the National Psoriasis Foundation.

Authors:  Amanda Robinson; Abby S Van Voorhees; Sylvia Hsu; Neil J Korman; Mark G Lebwohl; Bruce F Bebo; Robert E Kalb
Journal:  J Am Acad Dermatol       Date:  2012-05-18       Impact factor: 11.527

5.  Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis.

Authors:  R C Trembath; R L Clough; J L Rosbotham; A B Jones; R D Camp; A Frodsham; J Browne; R Barber; J Terwilliger; G M Lathrop; J N Barker
Journal:  Hum Mol Genet       Date:  1997-05       Impact factor: 6.150

6.  A systematic review of pharmacogenetic studies on the response to biologics in patients with psoriasis.

Authors:  L J van Vugt; J M P A van den Reek; M J H Coenen; E M G J de Jong
Journal:  Br J Dermatol       Date:  2017-12-14       Impact factor: 9.302

7.  The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study.

Authors:  Shanu Kohli Kurd; Andrea B Troxel; Paul Crits-Christoph; Joel M Gelfand
Journal:  Arch Dermatol       Date:  2010-08

8.  Patient benefits in the treatment of psoriasis: long-term outcomes in German routine care 2007-2014.

Authors:  M A Radtke; A Langenbruch; A Jacobi; M-L Schaarschmidt; M Augustin
Journal:  J Eur Acad Dermatol Venereol       Date:  2016-07-21       Impact factor: 6.166

9.  Psoriasis and the Risk of Major Cardiovascular Events: Cohort Study Using the Clinical Practice Research Datalink.

Authors:  Rosa Parisi; Martin K Rutter; Mark Lunt; Helen S Young; Deborah P M Symmons; Christopher E M Griffiths; Darren M Ashcroft
Journal:  J Invest Dermatol       Date:  2015-03-05       Impact factor: 8.551

10.  A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474.

Authors:  M P Cole; C T Jones; I D Todd
Journal:  Br J Cancer       Date:  1971-06       Impact factor: 7.640

View more
  2 in total

Review 1.  Towards Personalized Medicine in Psoriasis: Current Progress.

Authors:  Elisa Camela; Luca Potestio; Angelo Ruggiero; Sonia Sofia Ocampo-Garza; Gabriella Fabbrocini; Matteo Megna
Journal:  Psoriasis (Auckl)       Date:  2022-09-01

2.  Secukinumab Loss of Efficacy Is Perfectly Counteracted by the Introduction of Combination Therapy (Rescue Therapy): Data from a Multicenter Real-Life Study in a Cohort of Italian Psoriatic Patients That Avoided Secukinumab Switching.

Authors:  Giovanni Damiani; Giulia Odorici; Alessia Pacifico; Aldo Morrone; Rosalynn R Z Conic; Tima Davidson; Abdulla Watad; Paolo D M Pigatto; Delia Colombo; Piergiorgio Malagoli; Marco Fiore
Journal:  Pharmaceuticals (Basel)       Date:  2022-01-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.